{"id":2657,"text":"Rooibos extract, due to its glucose and lipid lowering effects, has potential as a nutraceutical for improvement of metabolic dysfunction.","label":[[0,7,"Herb name"],[8,15,"Extraction process"],[116,137,"Pathology"]],"Comments":[]}
{"id":2658,"text":"Potential herb-drug interactions as a result of the use of natural products are of increasing concern.","label":[],"Comments":[]}
{"id":2659,"text":"Cytochrome P450 enzymes, CYP2C8, CYP2C9, and CYP3A4, are important in the metabolism of hypoglycemic drugs, such as thiazolidinediones (TZDs) and sulfonylureas, and hypocholesterolemic drugs, such as atorvastatin.","label":[[0,23,"Target"],[25,31,"Target"],[33,39,"Target"],[45,51,"Target"],[88,106,"Drug"],[116,141,"Drug"],[146,159,"Drug"],[165,190,"Drug"],[200,212,"Drug"]],"Comments":[]}
{"id":2660,"text":"This study investigated the effects of rooibos extracts, prepared from “unfermented” and “fermented” rooibos plant material and two of the major bioactive compounds, Z-2-(β- Aspalathus linearis (Burm.f.)","label":[[39,46,"Herb name"],[47,55,"Extraction process"],[72,83,"Extraction process"],[90,99,"Extraction process"],[101,108,"Herb name"],[166,193,"Herb name"]],"Comments":[]}
{"id":2661,"text":"Dahlg.","label":[],"Comments":[]}
{"id":2662,"text":"(Fabaceae), a legume commonly referred to as rooibos, is a member of the fynbos biome native to the Western Cape region of South Africa.","label":[[1,9,"Herb name"],[45,52,"Herb name"]],"Comments":[]}
{"id":2663,"text":"The plant is processed to produce “unfermented” (green; unoxidised) and “fermented” (oxidised) rooibos, mainly for consumption as herbal tea [1].","label":[[34,67,"Extraction process"],[72,94,"Extraction process"],[95,102,"Herb name"],[137,140,"Herb name"]],"Comments":[]}
{"id":2664,"text":"Studies on the health benefits of fermented rooibos tea have confirmed that it alleviates oxidative stress [2], and has anti-mutagenic [3], anti-cancer [4,5,6], and anti-inflammatory [2] effects.","label":[[34,55,"Extraction process"],[44,55,"Herb name"],[90,106,"Pathology"]],"Comments":[]}
{"id":2665,"text":"Furthermore, rooibos extracts have been demonstrated to improve insulin resistance and related metabolic disturbances [7,8].","label":[[13,20,"Herb name"],[21,29,"Extraction process"],[64,82,"Pathology"],[95,117,"Pathology"]],"Comments":[]}
{"id":2666,"text":"The anti-diabetic [9,10], anti-obesity [11], and cardio-protective effects [12,13,14] of rooibos extracts are of specific relevance given the global increase in the prevalence of diabetes and obesity [15,16,17].","label":[[89,96,"Herb name"],[97,105,"Extraction process"],[179,187,"Pathology"],[192,199,"Pathology"]],"Comments":[]}
{"id":2667,"text":"These health promoting effects of rooibos have been attributed to its flavonoids including aspalathin, isoorientin, orientin, rutin, and nothofagin, as well as the phenylpropenoid glucoside, Z-2-(β- The use of natural products to improve general health or to treat a range of conditions has escalated in both developed and developing countries [26,27].","label":[[34,41,"Herb name"],[70,80,"Herb name"],[91,101,"Herb name"],[103,114,"Herb name"],[116,124,"Herb name"],[126,131,"Herb name"],[137,147,"Herb name"],[164,189,"Herb name"]],"Comments":[]}
{"id":2668,"text":"Natural products are perceived to be safer and without unwanted side effects attributed to conventional medicines.","label":[[64,76,"Pathology"]],"Comments":[]}
{"id":2669,"text":"This perception is greatly based on anecdotal evidence often without scientific verification.","label":[],"Comments":[]}
{"id":2670,"text":"Regardless, many plant-based nutraceuticals, including those derived from rooibos, are currently being developed or are already in use.","label":[[74,81,"Herb name"]],"Comments":[]}
{"id":2671,"text":"The safety and efficacy of such nutraceuticals as supplements and adjunctive therapies to chronic medications, specifically those used to treat metabolic disorders, such as type 2 diabetes and hyperlipidemia, have often not been established.","label":[[144,163,"Pathology"],[173,188,"Pathology"],[193,207,"Pathology"]],"Comments":[]}
{"id":2672,"text":"The adjunctive use of natural products with chronic medications for these metabolic disorders could potentially induce adverse herb-drug interactions.","label":[[74,93,"Pathology"]],"Comments":[]}
{"id":2673,"text":"Cytochrome P450 (CYP) enzymes are mainly responsible for the metabolism of drugs and other compounds including phytochemicals in the liver, kidney and intestines.","label":[[0,29,"Target"]],"Comments":[]}
{"id":2674,"text":"Approximately 80% of conventional drugs are metabolized by specific enzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4) belonging to subfamilies, CYP1, CYP2, and CYP3 [28,29].","label":[[77,83,"Target"],[85,91,"Target"],[93,100,"Target"],[102,108,"Target"],[110,116,"Target"],[122,128,"Target"],[156,160,"Target"],[162,166,"Target"],[172,176,"Target"]],"Comments":[]}
{"id":2675,"text":"Metformin, a first-line anti-diabetic drug, is metabolized by CYP2C11, CYP2D1, and CYP3A1\/2, while glyburide and pioglitazone, other known hypoglycemic drugs, are metabolized by CYP2C9, CYP3A4, and CYP2C8.","label":[[0,9,"Drug"],[24,42,"Drug"],[62,69,"Target"],[71,77,"Target"],[83,91,"Target"],[99,108,"Drug"],[113,125,"Drug"],[139,157,"Drug"],[178,184,"Target"],[186,192,"Target"],[198,204,"Target"]],"Comments":[]}
{"id":2676,"text":"Atorvastatin used to treat hypercholesterolemia is metabolized by CYP3A4.","label":[[0,12,"Drug"],[27,47,"Pathology"],[66,72,"Target"]],"Comments":[]}
{"id":2677,"text":"Inhibition of these specific CYPs by phytochemicals can affect the pharmacodynamics of these drugs, leading to toxicity or, alternatively, reduced efficacy [30].","label":[[29,33,"Target"]],"Comments":[]}
{"id":2678,"text":"When two substrates (phytochemicals and drugs) compete for the same receptor site, the more potent inhibitor will exert control over the weaker inhibitor, thus resulting in decreased metabolism of the respective substrate and, in the case where the drug is the weaker inhibitor, alter its pharmacodynamic properties [30].","label":[],"Comments":[]}
{"id":2679,"text":"Most drugs and xenobiotics including dietary polyphenols have the ability to bind to CYP3A4 as substrates.","label":[[45,56,"Herb name"],[85,91,"Target"]],"Comments":[]}
{"id":2680,"text":"The chemical structure of polyphenols and, specifically, their functional groups play an important role in their metabolism.","label":[[26,37,"Herb name"]],"Comments":[]}
{"id":2681,"text":"Flavonoids, common in the diet, are responsible for the modulation of the clinically relevant CYP2C8, CYP2C9, and CYP3A4 enzymes [31].","label":[[0,10,"Herb name"],[94,100,"Target"],[102,108,"Target"],[114,120,"Target"]],"Comments":[]}
{"id":2682,"text":"This modulation can alter drug metabolism through changes in the expression or activity of CYP enzymes, thereby affecting the plasma concentration of co-administered chronic medications [31].","label":[[91,102,"Target"]],"Comments":[]}
{"id":2683,"text":"The purpose of this study was, therefore, to investigate the inhibitory effects of polyphenol-enriched unfermented rooibos extract (GRT), and fermented rooibos extract (FRE), (Z-2-(β- High Performance Liquid Chromatography (HPLC) chromatograms of the extracts are depicted in Figure 1.","label":[[83,93,"Herb name"],[83,136,"Extraction process"],[143,173,"Extraction process"],[152,159,"Herb name"]],"Comments":[]}
{"id":2684,"text":"Content values for the individual compounds of the extracts are embedded in the respective chromatograms.","label":[],"Comments":[]}
{"id":2685,"text":"GRT contained substantially higher levels of flavonoids than FRE, largely due to its high aspalathin content.","label":[[0,3,"Extraction process"],[45,55,"Herb name"],[61,64,"Extraction process"],[90,100,"Herb name"]],"Comments":[]}
{"id":2686,"text":"It was the major compound in GRT, comprising ca.","label":[[29,32,"Extraction process"]],"Comments":[]}
{"id":2687,"text":"12% of the extract, compared to 0.36% of FRE.","label":[[41,44,"Extraction process"]],"Comments":[]}
{"id":2688,"text":"Compounds present in GRT at >1% were nothofagin, orientin, isoorientin, and quercetin-3-O-robinobioside.","label":[[21,24,"Extraction process"],[37,47,"Herb name"],[49,57,"Herb name"],[59,70,"Herb name"],[76,103,"Herb name"]],"Comments":[]}
{"id":2689,"text":"The PPAG content of GRT and FRE were 0.42% and 0.71%, respectively.","label":[[4,8,"Herb name"],[20,23,"Extraction process"],[28,31,"Extraction process"]],"Comments":[]}
{"id":2690,"text":"Qualitative screening of extracts and compounds was used to identify potential inhibitory effects on CYP2C8, CYP2C9 and CYP3A4.","label":[[101,107,"Target"],[109,115,"Target"],[120,126,"Target"]],"Comments":[]}
{"id":2691,"text":"The organic solvents such as methanol, acetonitrile and DMSO showed no inhibitory effects on the respective enzymes (Supplementary Materials, Figure S1a–c).","label":[],"Comments":[]}
{"id":2692,"text":"Quercetin, sulfaphenazole, and ketoconazole were the selected positive inhibitors for CYP2C8, CYP2C9, and CYP3A4, respectively.","label":[[0,9,"Herb name"],[11,25,"Drug"],[31,43,"Drug"],[86,92,"Target"],[94,100,"Target"],[106,112,"Target"]],"Comments":[]}
{"id":2693,"text":"GRT and FRE inhibited the reaction rate of CYP2C8, CYP2C9, and CYP3A4 as measured over 30 min (Figure 2a–c).","label":[[0,3,"Extraction process"],[8,11,"Extraction process"],[43,49,"Target"],[51,57,"Target"],[63,69,"Target"]],"Comments":[]}
{"id":2694,"text":"ASP showed 24% inhibition of CYP2C9 at 100 µg\/mL and 23% inhibition of CYP3A4 at 200 µg\/mL activity, while PPAG had no effect on any of these enzymes.","label":[[0,3,"Herb name"],[29,35,"Target"],[71,77,"Target"],[107,111,"Herb name"]],"Comments":[]}
{"id":2695,"text":"GRT and FRE showed strong inhibition of CYP2C8 activity (7.69 ± 8.85 µg\/mL and 8.93 ± 8.88 µg\/mL, respectively) (Figure 3a).","label":[[0,3,"Extraction process"],[8,11,"Extraction process"],[40,46,"Target"]],"Comments":[]}
{"id":2696,"text":"Both extracts moderately inhibited CYP3A4 activity (31.33 ± 4.69 µg\/mL and 51.44 ± 4.31 µg\/mL, respectively) (Figure 3b), while ASP displayed weak inhibition of CYP3A4 activity (69.57 ± 4.03 µg\/mL) (Figure 3b).","label":[[35,41,"Target"],[128,131,"Herb name"],[161,167,"Target"]],"Comments":[]}
{"id":2697,"text":"GRT and FRE reduced the remaining CYP2C8 activity in a moderate to strong concentration-dependent manner from 25 µg\/mL (70.1% and 82.1%, respectively; p < 0.001), 50 µg\/mL (31% and 39.7%, respectively; p < 0.001), and 100 µg\/mL (15.9% and 18.1%, respectively; p < 0.001) (Figure 4a).","label":[[0,3,"Extraction process"],[8,11,"Extraction process"],[34,40,"Target"]],"Comments":[]}
{"id":2698,"text":"ASP significantly inhibited CYP2C8 activity, albeit that the percentage remaining activity at 50 and 100 µg\/mL was still at 84.4% and 85.5%, respectively.","label":[[0,3,"Herb name"],[28,34,"Target"]],"Comments":[]}
{"id":2699,"text":"PPAG, ASP, GRT, and FRE did not significantly affect CYP2C9 enzyme activity (Figure 4b).","label":[[0,4,"Herb name"],[6,9,"Herb name"],[11,14,"Extraction process"],[20,23,"Extraction process"],[53,59,"Target"]],"Comments":[]}
{"id":2700,"text":"ASP, GRT, and FRE reduced CYP3A4 activity at 25 µg\/mL (62.9%, 36.9% and 61.4%, respectively; p < 0.001), 50 µg\/mL (44.5%, 13.5% and 29.7%, respectively; p < 0.001), and 100 µg\/mL (28.1%, 1.7% and 9.2%, respectively; p < 0.001) (Figure 4c).","label":[[0,3,"Herb name"],[5,8,"Extraction process"],[14,17,"Extraction process"],[26,32,"Target"]],"Comments":[]}
{"id":2701,"text":"Time-dependent screening determines the inactivation of enzymes by the ligand or metabolites of the ligand generated over time.","label":[],"Comments":[]}
{"id":2702,"text":"Both GRT and FRE showed time-dependent inhibition of CYP2C8 activity (Figure 5a).","label":[[5,8,"Extraction process"],[13,16,"Extraction process"],[53,59,"Target"]],"Comments":[]}
{"id":2703,"text":"GRT showed a slight increase (p < 0.01) in inhibition of CYP2C9 activity after approximately 15 min, however, this inhibitory effect was more noticeable than for the positive inhibitor, sulfaphenazole (Figure 5b).","label":[[0,3,"Extraction process"],[57,63,"Target"],[186,200,"Drug"]],"Comments":[]}
{"id":2704,"text":"PPAG demonstrated time-dependent inhibition (p < 0.05) of only CYP3A4 (Figure 5c).","label":[[0,4,"Herb name"],[63,69,"Target"]],"Comments":[]}
{"id":2705,"text":"ASP indicated no time-dependent inhibitory activity.","label":[[0,3,"Herb name"]],"Comments":[]}
{"id":2706,"text":"An interesting finding, however, is the time-dependent inhibition of CYP3A4 activity by GRT (p < 0.01) and FRE (p < 0.01), displaying a similar effect to that of erythromycin (Figure 5c).","label":[[69,75,"Target"],[88,91,"Extraction process"],[107,110,"Extraction process"]],"Comments":[]}
{"id":2707,"text":"The prevalent use of natural products for the treatment of various medical conditions has increased the potential of medicinal herbs to interact with conventional drugs when consumed concomitantly [32,33].","label":[],"Comments":[]}
{"id":2708,"text":"Interactions between components of herbal medicines and drugs could alter the pharmacodynamics and pharmacokinetics of the latter, leading to adverse reactions and toxic effects or reduced drug efficacy [34,35,36,37,38].","label":[[142,159,"Pathology"],[164,177,"Pathology"]],"Comments":[]}
{"id":2709,"text":"Herbal extracts contain many constituents that can contribute to their effects at different concentrations [39].","label":[],"Comments":[]}
{"id":2710,"text":"These constituents include various bioactive compounds that can either activate or inhibit CYP3A4 [31].","label":[[91,97,"Target"]],"Comments":[]}
{"id":2711,"text":"Echinacea purpurea, a known plant-based product with constituents such as caffeic acid derivatives, amides, flavonoids, and glycosides, displayed weak inhibitory effects of CYP3A4 activity with IC Recent studies demonstrated the potential use of rooibos extracts [8,11] and compounds, such as ASP [19] and PPAG [24,25], as anti-diabetic and\/or anti-obesity nutraceuticals.","label":[[0,18,"Herb name"],[74,86,"Herb name"],[100,106,"Herb name"],[108,118,"Herb name"],[124,134,"Herb name"],[173,179,"Target"],[194,196,"Parameter"],[246,253,"Herb name"],[254,262,"Extraction process"],[293,296,"Herb name"],[306,310,"Herb name"]],"Comments":[]}
{"id":2712,"text":"Plant extracts containing high levels of polyphenols are expected to have inhibitory effects on various CYPs including CYP2C8, CYP2C9, CYP2D6, and CYP3A4 [28,42].","label":[[41,52,"Herb name"],[104,108,"Target"],[119,125,"Target"],[127,133,"Target"],[135,141,"Target"],[147,153,"Target"]],"Comments":[]}
{"id":2713,"text":"Of these, CYP3A4 is commonly involved in herb-drug interactions as it metabolizes about 50% of clinically-prescribed medications [42,43,44].","label":[[10,16,"Target"]],"Comments":[]}
{"id":2714,"text":"Results obtained by Matsuda et al.","label":[],"Comments":[]}
{"id":2715,"text":"[45] for rats ingesting rooibos tea for two weeks suggested a possible interaction between rooibos tea and medicines mediated by CYP3A.","label":[[24,35,"Herb name"],[36,49,"Duration"],[91,102,"Herb name"],[129,134,"Target"]],"Comments":[]}
{"id":2716,"text":"No details of the type of rooibos tea (unfermented or fermented) used to prepare the infusion for feeding to the rats were provided.","label":[[26,37,"Target"],[39,50,"Extraction process"],[54,63,"Extraction process"],[85,93,"Extraction process"]],"Comments":[]}
{"id":2717,"text":"For the present study, two extracts of rooibos, GRT and FRE, were tested for their ability to inhibit selected CYPs.","label":[[39,46,"Herb name"],[48,51,"Extraction process"],[56,59,"Extraction process"],[111,115,"Target"]],"Comments":[]}
{"id":2718,"text":"GRT containing higher levels of polyphenols, in particular ASP (12.78% compared to 0.36%), demonstrated a more potent inhibition of CYP3A4 activity than FRE with IC CYP2C9 plays a role in the oxidation of xenobiotic and endogenous compounds and is responsible for the metabolism of 15%–20% of drugs undergoing phase I metabolism [52,53].","label":[[0,3,"Extraction process"],[32,43,"Herb name"],[59,62,"Herb name"],[132,138,"Target"],[153,156,"Extraction process"],[165,171,"Target"]],"Comments":[]}
{"id":2719,"text":"CYP2C9 is also involved in the metabolic clearance of therapeutic drugs such as oral hypoglycemics (pioglitazone, glyburide, and tolbutamide), cyclooxygenase-2 anti-inflammatories (celecoxib, ibuprofen, and naproxen), and oral anti-coagulants (warfarin) [29,30,51,54].","label":[[0,6,"Target"],[80,98,"Drug"],[100,112,"Drug"],[114,123,"Drug"],[129,140,"Drug"],[143,179,"Drug"],[181,190,"Drug"],[192,201,"Drug"],[207,215,"Drug"],[222,242,"Drug"],[244,252,"Drug"]],"Comments":[]}
{"id":2720,"text":"Changes in metabolic activity caused by genetic variants in CYP2C9 play a major role in the pathogenesis caused by adverse drug reactions [55].","label":[[60,66,"Target"],[115,137,"Pathology"]],"Comments":[]}
{"id":2721,"text":"Patients with low enzyme activity are at risk of adverse drug reactions from these CYP2C9 substrates [56].","label":[[49,71,"Pathology"],[83,89,"Target"]],"Comments":[]}
{"id":2722,"text":"We were unable to demonstrate a concentration dependent inhibitory effect for the extracts and ASP.","label":[[95,98,"Herb name"]],"Comments":[]}
{"id":2723,"text":"However, a partial time-dependent decrease in CYP2C9 activity was shown for GRT and FRE with GRT demonstrating stronger inhibitory potential than the competitive CYP2C9 inhibitor, sulfaphenazole.","label":[[46,52,"Target"],[76,79,"Extraction process"],[84,87,"Extraction process"],[93,96,"Extraction process"],[162,168,"Target"],[180,194,"Drug"]],"Comments":[]}
{"id":2724,"text":"When time-dependent inhibition is the major mode of action, the inhibitory effect of such a compound will be more prolonged specifically when multiple dosing is administered, such as the case for chronic medication [57].","label":[],"Comments":[]}
{"id":2725,"text":"Rooibos extracts, but not ASP or PPAG, when taken concomitantly with drugs, such as sulfonylureas, and specifically glyburide, could result in an exaggerated pharmacodynamic effect, thereby causing an increased risk of hypoglycemia [58,59].","label":[[0,7,"Herb name"],[8,16,"Extraction process"],[26,29,"Herb name"],[33,37,"Herb name"],[84,97,"Drug"],[116,125,"Drug"],[219,231,"Pathology"]],"Comments":[]}
{"id":2726,"text":"A strong concentration- and time-dependent inhibition of CYP2C8 activity was observed for both GRT and FRE.","label":[[57,63,"Target"],[95,98,"Extraction process"],[103,106,"Extraction process"]],"Comments":[]}
{"id":2727,"text":"However, ASP and PPAG had no effect on CYP2C8.","label":[[9,12,"Herb name"],[17,21,"Herb name"],[39,45,"Target"]],"Comments":[]}
{"id":2728,"text":"This suggests that other phytochemicals or synergistic interactions of constituents in the extract account for this inhibitory effect.","label":[],"Comments":[]}
{"id":2729,"text":"For compounds with the same basic flavonoid structure, the difference in inhibitory effect is related to their hydrophobicity [46].","label":[[34,43,"Herb name"]],"Comments":[]}
{"id":2730,"text":"Molecules more soluble in water do not make good substrates for P450 enzymes.","label":[[64,76,"Target"]],"Comments":[]}
{"id":2731,"text":"Both ASP and PPAG are water-soluble.","label":[[5,8,"Herb name"],[13,17,"Herb name"]],"Comments":[]}
{"id":2732,"text":"Other structural features of flavonoids that are important for their effect on CYPs are hydroxyl substitution (number and position) and the presence of double bonds [60].","label":[[29,39,"Herb name"],[79,83,"Extraction process"]],"Comments":[]}
{"id":2733,"text":"Luteolin, containing several hydroxyl groups on the A- and B-rings, inhibit metabolism of drugs such as midazolam, whereas tangeretin, also a flavone, but without free hydroxyl groups on the A- and B-ring (i.e., methoxylated), increases midazolam metabolism [46].","label":[[0,8,"Herb name"],[104,113,"Drug"],[123,133,"Herb name"],[142,149,"Herb name"],[237,246,"Drug"]],"Comments":[]}
{"id":2734,"text":"Clinically, this could lead to increased concentrations of TZDs present in the circulation, thereby potentially altering their therapeutic dose.","label":[[59,63,"Drug"]],"Comments":[]}
{"id":2735,"text":"This study demonstrates that GRT and FRE inhibited CYP2C8 and CYP3A4 activity in a dose- and time-dependent manner, whilst inhibiting CYP2C9 activity in a time-dependent manner only.","label":[[29,32,"Extraction process"],[37,40,"Extraction process"],[51,57,"Target"],[62,68,"Target"],[134,140,"Target"]],"Comments":[]}
{"id":2736,"text":"ASP could only be implicated in CYP3A4 inhibition.","label":[[0,3,"Herb name"],[32,38,"Target"]],"Comments":[]}
{"id":2737,"text":"PPAG did not display any inhibitory activities.","label":[[0,4,"Herb name"]],"Comments":[]}
{"id":2738,"text":"These results indicate that rooibos extracts may potentially cause herb-drug interactions when co-administered with substrates or drugs metabolized by these P450 enzymes.","label":[[28,35,"Herb name"],[36,44,"Extraction process"],[157,169,"Target"]],"Comments":[]}
{"id":2739,"text":"This will include chronic medications, such as hypoglycemics (TZDs and sulfonylureas) and hypolipidemics (atorvastatin and simvastatin).","label":[[47,60,"Drug"],[62,66,"Drug"],[71,84,"Drug"],[90,104,"Drug"],[106,118,"Drug"],[123,134,"Drug"]],"Comments":[]}
{"id":2740,"text":"As part of the drug discovery pipeline, it is important to demonstrate the potential of new therapeutics to interact with CYPs at a pre-clinical stage to avoid withdrawal once it enters the market.","label":[[122,126,"Target"],[132,150,"Study"]],"Comments":[]}
{"id":2741,"text":"Future research should identify possible phytoconstituents of rooibos likely implicated in the observed interactions.","label":[[62,69,"Herb name"]],"Comments":[]}
{"id":2742,"text":"A fermented rooibos extract (FRE), previously shown to have anti-diabetic properties [8,14], was used in this study.","label":[[2,33,"Extraction process"],[12,19,"Herb name"]],"Comments":[]}
{"id":2743,"text":"In addition, a pharmaceutical-grade unfermented rooibos extract, Afriplex GRT (GRT), with a high aspalathin (ca.","label":[[36,63,"Extraction process"],[65,77,"Herb name"],[79,82,"Extraction process"],[97,107,"Herb name"]],"Comments":[]}
{"id":2744,"text":"12%) content was also included in the study.","label":[],"Comments":[]}
{"id":2745,"text":"HPLC-diode array detection (DAD) quantification of the individual flavonoid and PPAG content of GRT was performed according to the method of Beelders et al.","label":[[66,75,"Herb name"],[80,84,"Herb name"],[96,99,"Extraction process"]],"Comments":[]}
{"id":2746,"text":"[61], as previously used for FRE (Figure 1b) [8].","label":[[29,32,"Extraction process"]],"Comments":[]}
{"id":2747,"text":"Z-2-(β- Ketoconazole, sulfaphenazole, erythromycin, quercetin, and solvents methanol, acetonitrile, and dimethyl sulfoxide (DMSO), were purchased from Sigma-Aldrich (St. Louis, MO, USA).","label":[[8,20,"Drug"],[22,36,"Drug"],[38,50,"Drug"],[52,61,"Herb name"]],"Comments":[]}
{"id":2748,"text":"Black Costar 96-well plates were obtained from Thermo Fischer Scientific (Pittsburgh, PA, USA).","label":[],"Comments":[]}
{"id":2749,"text":"Vivid The effect of organic solvents such as methanol, acetonitrile and DMSO on Vivid Compounds, PPAG and ASP, and the rooibos extracts, GRT and FRE, were screened for their inhibitory effects on CYP2C8, CYP2C9, and CYP3A4 using one-point screening kinetics.","label":[[97,101,"Herb name"],[106,109,"Herb name"],[119,126,"Herb name"],[127,135,"Extraction process"],[137,140,"Extraction process"],[145,148,"Extraction process"],[196,202,"Target"],[204,210,"Target"],[216,222,"Target"]],"Comments":[]}
{"id":2750,"text":"Stock solutions (10 mg\/mL) were prepared by diluting the extracts and compounds in distilled water.","label":[],"Comments":[]}
{"id":2751,"text":"Briefly, inhibitors, extracts, and compounds were pre-incubated with either CYP2C8 or CYP2C9 at a concentration of 100 µg\/mL, or CYP3A4 at a concentration of 200 µg\/mL.","label":[[76,82,"Target"],[86,92,"Target"],[129,135,"Target"]],"Comments":[]}
{"id":2752,"text":"In a black Costar 96-well plate, 3 µL of extracts or compounds (100 µg\/mL) were added to 57 µL of reaction buffer.","label":[],"Comments":[]}
{"id":2753,"text":"As per the manufacturer’s instruction, 50 µL of Vivid A three-fold serial dilution of PPAG, ASP, GRT, and FRE was added to CYP2C8 and CYP2C9 (concentration range 100–0.41 µg\/mL) and CYP3A4 (concentration range 200–0.82 µg\/mL) to determine their respective IC Time-dependent inhibition (TDI) using the respective serial dilutions employed for IC Stock solutions (10 mg\/mL) of PPAG, ASP, GRT, and FRE were prepared by dissolving the extracts and compounds in distilled water.","label":[[86,90,"Herb name"],[92,95,"Herb name"],[97,100,"Extraction process"],[106,109,"Extraction process"],[123,129,"Target"],[134,140,"Target"],[182,188,"Target"],[256,290,"Parameter"],[342,344,"Parameter"],[375,379,"Herb name"],[381,384,"Herb name"],[386,389,"Extraction process"],[395,398,"Extraction process"]],"Comments":[]}
{"id":2754,"text":"Thereafter, 3 µL of extracts or compounds (100 µg\/mL) were added to 57 µL of reaction buffer in a black Costar 96-well plate.","label":[],"Comments":[]}
{"id":2755,"text":"The following concentrations, 100, 50, 25, 10, and 5 µg\/mL were added to the plate in duplicate.","label":[],"Comments":[]}
{"id":2756,"text":"Inhibition of CYP2C8, CYP2C9, and CYP3A4 BACULOSOMES The data generated were exported to an Excel (Microsoft Headquarters, One Microsoft Way, Redmond, WA, USA) worksheet and the amount of metabolite formed at various concentrations relative to the control was calculated using the following equation:  The relative percentage activity was plotted against the log transformed concentrations of the extracts, compounds and positive controls, i.e.","label":[[14,20,"Target"],[22,28,"Target"],[34,40,"Target"]],"Comments":[]}
{"id":2757,"text":"quercetin (positive CYP2C8 inhibitor), sulfaphenazole (positive CYP2C9 inhibitor), and ketoconazole (positive CYP3A4 inhibitor).","label":[[0,9,"Herb name"],[20,26,"Target"],[39,53,"Drug"],[64,70,"Target"],[87,99,"Drug"],[110,116,"Target"]],"Comments":[]}
{"id":2758,"text":"A sigmoid curve was then fitted using a non-linear regression curve fit, dose response inhibition analysis was performed, and IC Data are means ± SEM.","label":[[126,128,"Parameter"]],"Comments":[]}
{"id":2759,"text":"The percentage remaining activity was analysed using two-way ANOVA with p < 0.05 considered significant.","label":[],"Comments":[]}
{"id":2760,"text":"Statistical analyses were performed using GraphPad Prism This in vitro study indicated that combining nutraceuticals containing rooibos extracts with drugs metabolized by CYP2C8 and CYP3A4 could potentially alter the pharmacodynamics and safety of these drugs.","label":[[62,76,"Study"],[128,135,"Herb name"],[136,144,"Extraction process"],[171,177,"Target"],[182,188,"Target"]],"Comments":[]}
{"id":2761,"text":"These findings still have to be confirmed in vivo.","label":[[42,49,"Study"]],"Comments":[]}
{"id":2762,"text":"This research was funded in part by the National Research Foundation (NRF) Thuthuka Programme (Grant 99381) and the Biomedical Research and Innovation Platform of the South African Medical Research Council.","label":[],"Comments":[]}
{"id":2763,"text":"Afriplex GRT™ was provided by Afriplex, Paarl, South Africa.","label":[[0,13,"Herb name"]],"Comments":[]}
{"id":2764,"text":"Sample Availability: Aspalathin is available from commercial sources.","label":[[21,31,"Herb name"]],"Comments":[]}
{"id":2765,"text":"Click here for additional data file.","label":[],"Comments":[]}
{"id":2766,"text":"Supplementary materials can be accessed at:  Charles Awortwe and Christo Muller contributed to the design of the study.","label":[],"Comments":[]}
{"id":2767,"text":"Oelfah Patel and Charles Awortwe performed the laboratory experiments and data analysis.","label":[],"Comments":[]}
{"id":2768,"text":"Oelfah Patel and Christo Muller wrote the manuscript.","label":[],"Comments":[]}
{"id":2769,"text":"Elizabeth Joubert provided the extracts and compositional data and gave input relating to the phytochemical aspects.","label":[],"Comments":[]}
{"id":2770,"text":"Johan Louw provided aspalathin and PPAG and contributed to writing the manuscript.","label":[[35,39,"Herb name"]],"Comments":[]}
{"id":2771,"text":"Bernd Rosenkranz helped with the pharmaceutical interpretation.","label":[],"Comments":[]}
{"id":2772,"text":"All authors reviewed the manuscript.","label":[],"Comments":[]}
{"id":2773,"text":"The authors declare no conflict of interest.","label":[],"Comments":[]}
{"id":2774,"text":"The founding sponsors had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.","label":[],"Comments":[]}
{"id":2775,"text":"HPLC chromatograms of (a) FRE (fermented rooibos extract) and (b) GRT (unfermented rooibos extract) at 288 and 350 nm (solid and dotted lines, respectively).","label":[[26,57,"Extraction process"],[66,99,"Extraction process"]],"Comments":[]}
{"id":2776,"text":"Content values of compounds are expressed as g\/100 g extract (1, PPAG (Z-2-(β-D-glucopyranosyloxy)-3-phenylpropenoic acid), 2, isoorientin; 3, orientin; 4, ASP (aspalathin); 5, quercetin-3-O-robinobioside; 6, vitexin; 7, hyperoside; 8, rutin; 9, isovitexin; 10, isoquercetrin; 11, luteolin-7-O-glucoside, and 12, nothofagin).","label":[[65,122,"Herb name"],[127,138,"Herb name"],[143,151,"Herb name"],[156,172,"Herb name"],[177,204,"Herb name"],[209,216,"Herb name"],[221,231,"Herb name"],[236,241,"Herb name"],[246,256,"Herb name"],[262,275,"Herb name"],[281,303,"Herb name"],[313,323,"Herb name"]],"Comments":[]}
{"id":2777,"text":"Qualitative screening of drugs, compounds and extracts based on their inhibitory potency of Vivid Percentage remaining activity of (a) CYP2C8 and (b) CYP3A4 after 30 min co-incubation with ASP (aspalathin), GRT (unfermented rooibos extract) and FRE (fermented rooibos extract) with NADPH and substrates.","label":[[135,141,"Target"],[150,156,"Target"],[189,205,"Herb name"],[207,240,"Extraction process"],[245,276,"Extraction process"],[282,287,"Target"]],"Comments":[]}
{"id":2778,"text":"Data are the average values of two independent assays done in duplicate (n = 4).","label":[],"Comments":[]}
{"id":2779,"text":"Percentage remaining activity of (a) CYP2C8; (b) CYP2C9 and (c) CYP3A4 following 30 min pre-incubation with PPAG (Z-2-(β- Screening of PPAG (Z-2-(β- Structures of (a) aspalathin and (b) phenylpyruvic acid glucoside (PPAG) where R = β-","label":[[37,43,"Target"],[49,55,"Target"],[64,70,"Target"],[108,112,"Herb name"],[135,139,"Herb name"],[167,177,"Herb name"],[186,221,"Herb name"]],"Comments":[]}
